Adolescent Mental Health: Canadian Psychiatric Risk and Outcome Study (PROCAN)

University of Calgary

Status: Completed

Conditions: Psychotic Disorders; Bipolar Disorder; Depressive Disorder, Major

Study type: Observational

Funder types: Other

Identifiers

NCT02739932

MIRI-14-3377

Details and patient eligibility

About

The primary study aims are to determine the clinical, behavioural and social predictors of SMI development in youth, and to investigate whether neuroimaging can distinguish youth who will develop SMI from those who will not.

The study's secondary aims are to examine the proportions of the cohort that make transitions between the different clinical stages of risk, and to determine the proportions that have poor outcomes, defined as ongoing or increased symptoms, secondary substance misuse, poor social or role functioning, i.e., non-participation in education, or employment, and new self-harm.

Investigators will study a cohort of 240 youth (aged 14-25, male and female) that includes youth with early mood symptoms or sub-threshold psychotic symptoms (symptomatic group; n=160), youth at risk due to a family history of a SMI (family high risk (FHR); n=40), and healthy controls (HC; n=40). From this cohort, clinical, social and cognitive data, as well as imaging data will be gathered to create a multi-layered "snapshot" of these individuals and provide full-level characterization. Investigators will use the full range of clinical and imaging data generated from this cohort to develop novel prediction algorithms incorporating key variables that predict the development of SMI.

Enrollment: 243 patients

Sex: All

Ages: 12 to 25 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Participants will understand and sign an informed consent (or assent for minors) document in English.

Exclusion criteria

• meet criteria for current or lifetime Axis I bipolar or psychotic disorder (other Axis I disorders will not be exclusionary as they may be precursors to mood or psychotic disorders);
• IQ < 70;
• past or current history of a significant central nervous system disorder or serious medical disorder; and
• current pharmacological treatment that would be considered as an adequate trial of treatment for a SMI.